Retraction: Modern Rapidly Degradable Hydroxyethyl Starches: Current Concepts (Journal of Physical Chemistry (2009) 108 (1574-1582) DOI: 10.1213/ane.0b013e31819e9e6c);Modern rapidly degradable hydroxyethyl starches: Current concepts

Anesthesia and Analgesia

Volumn 108, Issue 5, 2009, Pages 1574-1582

  Boldt, Joachim ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; HEMOHES; HETASTARCH; PLASMA VOLUME READYBAG; PLASMATERIL; SODIUM; TETRASPAN; UNCLASSIFIED DRUG; VENOFUNDIN; VOLULYTE; PLASMA SUBSTITUTE; SOLVENT;

ANAPHYLAXIS; BLEEDING TENDENCY; BLOOD CLOTTING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPOVOLEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; BLEEDING; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; KIDNEY DISEASE; METABOLIC CLEARANCE RATE; MOLECULAR WEIGHT; RISK ASSESSMENT; TREATMENT OUTCOME;

ANAPHYLAXIS; BLOOD COAGULATION; HEMORRHAGE; HETASTARCH; HUMANS; HYPOVOLEMIA; KIDNEY DISEASES; METABOLIC CLEARANCE RATE; MOLECULAR WEIGHT; PLASMA SUBSTITUTES; PRURITUS; RISK ASSESSMENT; SOLVENTS; TREATMENT OUTCOME;

EID: 65349085592     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000005019     Document Type: Erratum

References (63)

1. Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005;44:681-99
2. Schortgen F, Deye N, Brochard L; CRYCO Study Group. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 2004;30:2222-9
3. Waitzinger J, Bepperling F, Pabst G, Opitz J. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacoki-netics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003;4:149-57
4. Lehmann G, Marx G, Förster H. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6:1 and hydroxyethyl starch 130/0.4/9:1. Drugs R D 2007;8:229-40
5. deJonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-7
6. Sanfelippo MJ, Suberviola PD, Geimer NF. Development of a von Willebrand-like syndrome after prolonged use of hydroxy-ethyl starch. Am J Clin Pharmacol 1987;88:653-5
7. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensive Care Med 1999;25:258-68
8. Madjdpour C, Dettori N, Frascarolo P, Burki M, Boll M, Fisch A, Bombeli T, Spahn DR. Molecular weight of hydroxyethyl starch: is there an effect on blood coagulation and pharmacokinetics? Br J Anaesth 2005;94:569-76
9. Strauss RG, Pennell BJ, Stump DC. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion 2002;42:27-36
10. Haynes GH, Havidich JE, Payne KJ. Why the Food and Drug Administration changed the warning label for hetastarch. Anesthesiology 2004;101:560-1
11. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997;78:974-83
12. Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology 2005;103:654-60
13. Stögermüller B, Stark J, Willschke H, Felfernig M, Hoerauf K, Kozek-Langenecker SA. The effect of hydroxyethylstarch 200 kD on platelet function. Anesth Analg 2000;91:823-7
14. Franz A, Bräunlich P, Gamsjäger T, Felfernig M, Gustorff B, Kozek-Langenecker SA. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 2001;92:1402-7
15. Konrad CJ, Markl TJ, Schuepfer K, Schmeck J, Gerber HR. In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT. Anesth Analg 2000;90:274-9
16. Felfernig M, Franz A, Bräunlich P, Fohringer C, Kozek-Langenecker SA. The effects of hydroxyethyl starch solutions on thromboelastography in preoperative male patients. Acta Anaesthesiol Scand 2003;47:70-3
17. Gallandat Huet RCG, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, Bepperling F. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-15
18. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new hydroxyetyhlstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001;15:316-21
19. Kasper SM, Meinert P, Kampe S, Görg C, Geisen C, Mehlhorn U, Diefenbach C. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003;99:42-7
20. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D 2004;5:1-9
21. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008;107:382-90
22. Scharbert G, Deusch E, Kress HG, Greher M, Gustorff B, Kozek-Langenecker SA. Inhibition of platelet function by hy-droxyethyl starch solutions in chronic pain patients undergoing peridural anesthesia. Anesth Analg 2004;99:823-7
23. Chen G, Yan M, Lu QH, Gong M. Effects of two different hydroxyethyl starch solutions (HES200/0.5 vs.HES130/0.4) on the expression of platelet membrane glycoprotein. Acta Anaes-thesiol Scand 2006;50:1089-94
24. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Innerhofer P. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007;105:905-17
25. Boldt J, Wolf M, Mengistu A. A new plasma-adapted hydroxy-ethylstarch preparation: in vitro coagulation studies using thrombelastography and whole blood aggregometry. Anesth Analg 2007;104:425-30
26. Boldt J, Mengistu A, Seyfert UT, Vogt A, Hellstern P. The impact of a medium molecular weight, low molar substitution hy-droxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro. Vox Sang 2007;93:139-44
27. Kief H, Englelhart K. Reabsorptive Vacuolisation der gewun-denen Nierenhauptstuecke (sog. osmotische Nephrose). Frank Zeitschr Path 1966;75:53-9
28. Chinitz JL, Kim KE, Onesti G, Swartz C. Pathophysiology and prevention of dextran-40- induced anuria. J Lab Clin Med 1971;77:76-87
29. Rozich JD, Paul RV. Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 1989;87:358-60
30. Legendre C, Thervet E, Page B, Percheron A, Noël LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248-9
31. Cittanova ML, LeBlanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effects of hydroxyethyl starch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-2
32. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicenter randomised study. Lancet 2001;357:911-6
33. Brunkhorst FM, Englel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. German competence network sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39
34. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008;24;8:1
35. Davidson IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006;23:721-38
36. Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, Marx G, Vincent JL. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007;98:216 -24
37. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 2003;29:763-9
38. Blasco V, Leone M, Antonini F, Geissler A, Albanèse J, Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 2008;100:504-8
39. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxy-ethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003;96:1453-9
40. Boldt J, Brosch Ch, Röhm K, Papsdorf M, Mengistu A. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br J Anaesth 2008;100:457-64
41. Boldt J, Brosch Ch, Röhm K, Lehmann A, Mengistu A, Suttner S. Is albumin administration in hypolbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kideny function? Anesth Anlag 2008;107:1496-503
42. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 2002;95:544-51
43. Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P. Safety of HES 130/0.4 (Voluven) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial. Eur J Anaesthesiol 2008;20:1-9
44. Boldt J, Brosch C, Ducke M, Papsdorf M, Lehmann A. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 2007;35:2740-6
45. Fisher MM, Brady PW. Adverse reactions to plasma volume expanders. Drug Saf 1990;5:86-93
46. Allhoff T, Lenhart FP. Severe dextran-induced anaphylayctic/ anaphylactoid reaction inspite of hapten prophylaxis. Infusion-sther Transfusionsmed 1993;20:301-6
47. Laxenaire M, Charpentier C, Feldman L. Reactions anaphylac-toides aux subitutes colloidaux du plasma: incidence, facteurs de risque, mecanismes. Ann Fr Anest Reanimat 1994;13:301-10
48. Shatney CH, Chaudry ICH. Hydroxethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis. Circ Shock 1984;13:21-2
49. Lehmann GB, Asskali F, Boll M, Burmeister MA, Marx G, Hilgers R, Förster H. HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 2007;98:635-44
50. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997;136:553-9
51. Spittal MJ, Findlay GP. The seven year itch. Anaesthesia 1995;50:913- 4
52. Gröchenig E, Albegger K, Dieterich HJ. Hydroxyethylstarch-related pruritus: a prospective multicentre investigation in 544 patients. Perfusion 1998;11:62-9
53. Bothner U, Georgieff M, Vogt NH. Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study. Anesth Analg 1998;86:850-6
54. Woessner R, Grauer MT, Dieterich HJ, Bepperling F, Baus D, Kahles T, Georgi S, Bianchi O, Morgenthaler M, Treib J. Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Results of a randomized, placebo-controlled, double-blind study. Pathophysiol Haemost Thromb 2003;33:121-6
55. Rudolf J; HES in Acute Stroke Study Group. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002;14:33-41
56. Klemm E, Bepperling F, Burschka MA, Mösges R. Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a dose-finding, double-blind, placebo-controlled, international multi-center trial with 210 patients. Otol Neurotol 2007;28:157-70
57. Kasper SM, Strömich A, Kampe S, Radbruch L. Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation. J Clin Anesth 2001;13:486-90
58. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56
59. Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 2003;123:1853-7
60. Webb AR. Crystalloid or colloid resuscitation. Are we any wiser? Crit Care 1999;3:R25-R28
61. Astiz ME, Rackow EC. Crystalloid-colloid controversy revisited. Crit Care Med 1999;27:34-5
62. Cook D, Guyatt G. Editorial: colloid use for fluid resuscitation - evidence and spin. Ann Intern Med 2001;135: 205-8
63. Warren BB, Durieux ME. Hydroxyethyl starch: safe or not? Anesth Analg 1997;84:206-12